Chemomab Therapeutics Ltd. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Chemomab Therapeutics Ltd. (CMMB) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $2.92 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Notes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-23
- Chemomab Therapeutics Ltd. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $5.20M, a 100.00% increase from fiscal 2021.
- Chemomab Therapeutics Ltd. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $2.60M, a 49.02% decline from fiscal 2020.
- Chemomab Therapeutics Ltd. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $5.10M, a 26.09% decline from fiscal 2019.
- Chemomab Therapeutics Ltd. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2019 was $6.90M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.92M 20-F · filed 2026-03-23 | |
| 2024-12-31 | $3.21M 20-F · filed 2026-03-23 | $800.00K 20-F · filed 2025-04-04 |
| 2023-12-31 | $5.57M 20-F · filed 2026-03-23 | $2.30M 20-F · filed 2024-03-28 |
| 2022-12-31 | $5.20M 10-K · filed 2023-03-20 | |
| 2021-12-31 | $2.60M 10-K · filed 2022-03-30 | |
| 2020-12-31 | $5.10M 10-K · filed 2021-03-09 | |
| 2019-12-31 | $6.90M 10-K · filed 2020-03-17 |